Literature DB >> 30614901

Corneal Endothelial Cell Density and Morphology After Phacoemulsification in Patients With Primary Open-Angle Glaucoma and Cataracts: 2-Year Results of a Randomized Multicenter Trial.

Tsontcho Ianchulev1, Stephen Lane2,3, Marisse Masis4, Jonathan H Lass5,6, Beth Ann Benetz5,6, Harry J Menegay5,6, Francis W Price7, Shan Lin4.   

Abstract

PURPOSE: To evaluate corneal endothelial cell density (ECD) and morphology 2 years after phacoemulsification in subjects from the COMPASS trial (ClinicalTrials.gov, NCT01085357) who had mild-to-moderate primary open-angle glaucoma and visually significant cataracts.
METHODS: The central corneal endothelium was evaluated by serial specular microscopy at 0 to 24 months. ECD, coefficient of variation, and percentage of hexagonal cells were evaluated by a central image analysis reading center and central corneal thickness (CCT) was evaluated by ultrasound pachymetry.
RESULTS: Of 131 subjects who underwent routine phacoemulsification, analyzable endothelial images at 24 months were available for 126 subjects (96.2%). Mean ± SD central ECD at baseline was 2453 ± 359 cells/mm, decreasing by 10% ± 14% to 2195 ± 517 cells/mm at 3 months (P < 0.001) but stabilizing thereafter with mean endothelial cell loss (ECL) from baseline to 24 months of 9% ± 13% (P < 0.001). Twelve (9.5%) and 10 (7.9%) subjects experienced >30% ECL at 12 and 24 months, respectively. Neither coefficient of variation nor percentage of hexagonal cells changed significantly from baseline at any time point. Mean CCT was similar at baseline (550 ± 35 μm) and at 12 months (551 ± 37 μm) and 24 months (555 ± 35 μm). Age was significantly associated with ECL after cataract surgery (P = 0.02), but baseline intraocular pressure, number of glaucoma medications, and CCT were not. Similar results were observed in patients who underwent CyPass micro-stent implantation accompanying phacoemulsification.
CONCLUSIONS: Phacoemulsification in eyes with mild-to-moderate primary open-angle glaucoma results in early ECL, with ECD stabilizing after 3 months and no effect on other endothelial stress markers up to 2 years postoperatively.

Entities:  

Mesh:

Year:  2019        PMID: 30614901     DOI: 10.1097/ICO.0000000000001826

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  5 in total

1.  Corneal Edema and Keratoplasty: Risk Factors in Eyes With Previous Glaucoma Drainage Devices.

Authors:  Bradley Beatson; Jiangxia Wang; Michael V Boland; Pradeep Ramulu; Oliver Schein; Michael J Fliotsos; Michael E Sulewski; Divya Srikumaran
Journal:  Am J Ophthalmol       Date:  2022-01-05       Impact factor: 5.488

2.  The Effect of Tube Location on Corneal Endothelial Cells in Patients with Ahmed Glaucoma Valve.

Authors:  Qi Zhang; Yingna Liu; Sukhumal Thanapaisal; Julius Oatts; Yetao Luo; Gui-Shuang Ying; Junming Wang; Stephen D McLeod; Steven J Gedde; Ying Han
Journal:  Ophthalmology       Date:  2020-06-27       Impact factor: 12.079

3.  Predictors of Endothelial Cell Loss after Phacoemulsification for the Treatment of Primary Angle Closure.

Authors:  Carlo Alberto Cutolo; Chiara Bonzano; Carlo Catti; Alessandro Bagnis; Riccardo Scotto; Letizia Negri; Sara Olivari; Francesca Cappelli; Carlo Enrico Traverso
Journal:  J Ophthalmol       Date:  2019-07-28       Impact factor: 1.909

4.  Accelerated Corneal Endothelial Cell Loss after Phacoemulsification in Patients with Mildly Low Endothelial Cell Density.

Authors:  Hung-Chi Chen; Chen-Wei Huang; Lung-Kun Yeh; Fang-Chi Hsiao; Yi-Jen Hsueh; Yaa-Jyuhn James Meir; Kuan-Jen Chen; Chao-Min Cheng; Wei-Chi Wu
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

5.  Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial.

Authors:  Philippe Denis; Christoph Hirneiß; Georges M Durr; Kasu Prasad Reddy; Anita Kamarthy; Ernesto Calvo; Zubair Hussain; Iqbal K Ahmed
Journal:  Br J Ophthalmol       Date:  2020-10-03       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.